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Delivery technologiesThe dramatic rise of the twin epidemics, type 2 diabetes and obesity is associated with increased mortal-
ity and morbidity worldwide. Based on this global development there is clinical need for anti-diabetic
therapies with accompanied weight reduction. From the approved therapies, the injectable glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) are the only class of agents which are associated with a modest
weight reduction. Physiological effects of the gastro-intestinal hormone GLP-1 are improvement of gly-
cemic control as well as a reduction in appetite and food intake. Different approaches are currently under
clinical evaluation to optimize the therapeutic potential of GLP-1 RAs directed to once-weekly up to once-
monthly administration. The next generation of peptidic co-agonists comprises the activity of GLP-1 plus
additional gastro-intestinal hormones with the potential for increased therapeutic beneﬁts compared to
GLP-1 RAs.
 2013 Elsevier Ltd. All rights reserved.Introduction. Type 2 diabetes mellitus (T2DM) is a progressive
chronic disease characterized by hyperglycemia due to defective
insulin secretion and resistance to insulin action. The disease is
associated with morbidity and mortality in patients, and is a lead-
ing cause for cardiovascular (CV) disease, renal failure, blindness,
amputations and hospitalizations.1,2 T2DM has recently reached
epidemic proportions in both developed and developing countries
in conjunction with a substantial increase in obesity.3 Up to 80% of
people with T2DM are overweight or obese, whereas obesity is
considered as a major risk factor for T2DM.4 ‘Diabesity’ is a new
term to characterize this phenomenon of obesity-dependent diabe-
tes associated with multiple comorbidities (mainly CV disease) and
in addition describes a rising epidemic.5 An effective approach to
the management of diabesity is a modest reduction in body weight
(4–5 kg) resulting in highly beneﬁcial effects on glycemic control
as well as reduced morbidity and mortality.4 According to the new
guidelines of the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD) out of avail-
able classes of glucose-lowering agents, the only class associated
with modest body weight reduction are peptidic glucagon-like
peptide-1 receptor agonists (GLP-1 RAs). All other agents are either
weight neutral (Metformin, DPP4-inhibitors) or associated with
weight gain (basal insulin, thiazolidinediones, sulfonylureas).6Therapy with peptidic GLP-1 RAs is based on self-administra-
tion by subcutaneous injection using a pen device (or a syringe).
The following GLP-1 RAs are approved for the treatment of diabe-
tes: twice-daily exenatide BID (Byetta, BMS), once-daily lixisena-
tide (Lyxumia, Sanoﬁ/Zealand), once-daily liraglutide (Victoza,
Novo Nordisk) and once-weekly exenatide LAR (Bydureon, BMS).
Current optimization of peptidic GLP-1 RAs aims to improve
efﬁcacy, tolerability and compliance such as frequency and ease
of administration. Furthermore, signiﬁcant efforts are currently
undertaken to identify therapeutic peptide approaches with the
potential for greater body weight reduction compared to existing
GLP-1 RAs. The present article reviews key data on marketed and
novel long-acting GLP-1 RAs currently in late clinical development,
describes novel techniques suitable for once-weekly up to once-
monthly administration and discusses potential novel peptide ap-
proaches based on further gut hormones. However, recent research
activities have resulted also in peptidic and small molecule GLP-1
RAs which might be suited for oral application7–among those
TTP054 from Transtech Pharma as most advanced in phase 2.8
Those still early developments in the ﬁeld of orally available
GLP-1 RAs are not covered by this review.
GLP-1 RAs: overview. Natural human glucagon-like peptide-1
(GLP-1) is an incretin hormone derived from the transcription
product of the proglucagon gene. It is produced by intestinal L-cells
and released in response to meal intake to induce insulin secretion
from pancreatic b-cells. The biologically active forms of GLP-1 are
GLP-1(7–37) and GLP-1(7–36)NH2, which exert their action by
activation of the GLP-1 receptor, a class B G-protein-coupled
receptor. GLP-1 shows a helical character in solution and in the
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potent peptidic GLP-1 RA, which was isolated from the venom of
the Gila monster. Although it shares only 53% sequence identity
with native GLP-1, both peptides show a helical character with
many of the conserved amino acids facing the interaction site of
the receptor (see Fig. 1).11 All GLP-1 RAs on the market or in clinical
development are either derived from the natural GLP-1 or exendin-
4 peptide. Based on their PK-proﬁle, marketed GLP-1 RAs exenatide
BID and lixisenatide could be classiﬁed as shorter-acting agents
compared with longer-acting agents liraglutide and exenatide LAR.
GLP-1 and GLP-1 RAs have 3 major pharmacological activi-
ties12,13 to improve glycemic control in patients with T2DM by
reducing fasting and postprandial glucose (FPG and PPG): (i) in-
creased glucose-dependent insulin secretion (improved ﬁrst- and
second-phase), (ii) glucagon suppressing activity under hypergly-
cemic conditions, (iii) delay of gastric emptying rate resulting in re-
tarded absorption of meal-derived glucose. Treatment with GLP-1
RAs for 12–52 weeks leads to reduction in glycosylated hemoglo-
bin (HbA1c), a diagnostic marker reﬂecting the average glucose
levels of the last 2–3 months (and serving as primary efﬁcacy end-
point in phase 2b–3 studies) of 1.1–1.6% due to reduced postpran-
dial and fasting blood glucose.14 Unlike insulin or insulin
secretagogues (sulfonylureas) the insulinotropic effect of GLP-1
RAs is strictly glucose-dependent resulting in a generally low risk
for hypoglycemia. Beyond anti-hyperglycemic actions of GLP-1
RAs, central and possibly peripheral effects (e.g. vagal afferents)
which modulate feelings of appetite and satiety are considered to
reduce food intake and ﬁnally account for a moderate body weight
reduction in the range of 1–3 kg.15
In addition, beneﬁcial reduction in systolic and diastolic blood
pressure as well as reduced cholesterol plasma levels were ob-
served in clinical trials.16 Preclinical data illustrate different cardio-
protective effects of GLP-1 RAs (e.g. on cardiomyocytes, blood
vessels, adipocytes and lipids).17 These effects might impair the on-
set or progression of atherosclerotic disease. Furthermore, animal
and initial clinical studies have shown that GLP-1 RAs could reduce
ischemia–reperfusion injury. However, treatment with longer-Figure 1. Binding hypotheses of GLP-1 RAs at the GLP-1R. Amino acid changes versus nat
binding modes of the remaining peptides are computational models.acting GLP-1 RAs (liraglutide and exenatide LAR) is accompanied
in humans by a slight increase in heart rate of 2–4 beats per min-
ute. Ongoing cardiovascular outcome studies for the marketed
agents will reveal if the potential harm of an increased heart rate
will be outweighed by the reported cardiovascular beneﬁts.17
The most common side effects of GLP-RAs are nausea, vomiting
and diarrhea, which are mostly transient and can be at least partly
reduced by gradual uptitration of the dose. Beyond gastro-intesti-
nal side effects an association of long-term GLP-1RA therapy with
an increased risk for pancreatitis is under discussion. Some rare
cases of acute pancreatitis have been reported as postmarketing
surveillance activities for GLP-1 RAs. It is not clear if such cases
are therapy-related or due to a general 2–3-fold increased risk
for acute pancreatitis associated with T2DM.18 In rodents malig-
nant thyroid C-cell carcinomas were observed following treatment
with liraglutide. The human relevance of these ﬁndings in rodents
could not be determined by clinical or nonclinical studies.18
As peptide based drugs, GLP-1 RAs have the potential to induce
an immune response and antibody formation was reported for all
marketed GLP-1 RAs but does not appear to impact efﬁcacy or
safety of these agents. The level of glycemic control (HbA1c) is
overall reported similar regardless of the antibody status, although
for a rare number of patients high-titer antibody formation might
be associated with attenuated glycemic response (reported for 1–
4% of total patients treated with exenatide BID).19 There seems to
be slightly increased antibody development and injection site reac-
tions with exendin-4 compared to the GLP-1 analog liraglutide,20
presumably due to the greater differences in sequence identity
compared to native GLP-1.
A differentiating characteristic within the GLP-1 RA class impor-
tant for glycemic control is the propensity to slow gastric empty-
ing, which is dependent on the pharmacokinetics of these agents.
For longer-acting agents such as liraglutide and exenatide LAR, de-
layed gastric emptying fades following the ﬁrst dose probably
reﬂecting tachyphylaxis.21,22 These agents strongly reduce fasting
blood glucose probably via continuous increased insulin levels in
the fasting state and cause an apparently better efﬁcacy thanive GLP-1 are shown in orange. Binding mode of GLP-1 from RCSB PDB (PDB ID 3iol),
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exenatide BID and lixisenatide are both proven to strongly slow
gastric emptying in patients with T2DM without any signs for
desensitization with continuous treatment.23,24 As consequence,
shorter-acting GLP-1 RAs are associated with a pronounced reduc-
tion in PPG. As HbA1c levels decrease under therapy, the contribu-
tion of postprandial glucose to HbA1c increases over that of fasting
plasma glucose.25 For patients with improved HbA1c under ther-
apy (including those on insulin treatment), who have a greater
dependency on postprandial glucose, shorter-acting agents may
be the better choice. This greater PPG-lowering effect of shorter-
acting GLP-1 RAs would be complementary to the glucose lowering
effects of basal insulin, which primarily targets fasting glucose.
Hence, a combination therapy of shorter-acting GLP-1 RAs with ba-
sal insulin may offer the advantage to lower basal insulin require-
ments and result in beneﬁcial weight loss effects.26
GLP-1 agonists on the market and in clinical development. Thera-
peutic utility of natural GLP-1 is limited by its rapid degradation by
serum proteases, predominantly dipeptidyl peptidase IV (DPPIV),
but also other enzymes such as neutral endopeptidase (NEP), plas-
ma kallikrein or plasmin.27 Therefore, GLP-1 has a very short half-
life of 2 min following intravenous administration. A variety of
strategies have been applied to provide novel GLP-1 RAs with
longer-term in vivo activity following subcutaneous administra-
tion, which are described below.
Peptides stabilized against DPPIV by amino acid exchange. One
strategy to prolong in vivo half-life is stabilization towards degra-
dation by DPPIV, which preferably cleaves N-terminal Xaa–Pro or
Xaa–Ala dipeptide sequences. Alteration of that N-terminal se-
quence, especially the second amino acid, has proven to reduce
degradation by DPPIV.28,29
Exenatide BID. In exendin-4, the second amino acid is a Gly ren-
dering it resistant to DPPIV mediated degradation. Furthermore,
the Leu21–Ser39 span of exendin-4 forms a compact tertiary fold
(the Trp-cage) which shields the side chain of Trp25 from solvent
exposure, leading to enhanced helicity and stability of the peptide
(see Fig. 1).9 Exenatide BID (Amylin, now BMS), a synthetic version
of exendin-4, represents the ﬁrst GLP-1 RA approved in 2005 as
antidiabetic therapy for the treatment of T2DM. It has a terminal
half-life of 2.4 h after subcutaneous administration and is applied
twice daily (10 lg). With this dosing regimen as monotherapy or in
combination with oral antidiabetics, HbA1c reductions of 0.8–0.9%
are typically observed accompanied by a body weight reduction in
the range of 1.8–2.6 kg following a treatment duration of 30 weeks.
In an open label extension the combination of exenatide BID and
metformin showed a HbA1c reduction of 1.1% and a body weight
reduction of 4.4 kg after 82 weeks.30 Exenatide BID and insulin
glargine did not demonstrate a signiﬁcant difference in HbA1c
reduction (1.25% vs 1.26%) after 26 weeks treatment. However,
insulin glargine resulted in a weight gain of 3 kg compared to a
reduction of 2.7 kg seen with exenatide BID.31
Lixisenatide. Lixisenatide, developed by Sanoﬁ/Zealand, is a syn-
thetic analog of exendin-4 (Fig. 1). Compared to exendin-4, six Lys
residues have been added to the C-terminus (also amidated), while
one Pro in the C-terminal region has been deleted. Lixisenatide has
a mean terminal half-life of approximately 3 h in humans. In a
dose-ranging study in patients with T2DM, inadequately con-
trolled with metformin, lixisenatide at a dose of 20 lg once-daily
demonstrated the best efﬁcacy-to-tolerability ratio.32 Lixisenatide
was applied as once-daily administration (20 lg) in phase 3 trials
and has demonstrated efﬁcacy as monotherapy, in combination
with oral antidiabetic drugs, and as add-on to basal insulin, with
particular efﬁcacy in reducing postprandial glucose excursion
(HbA1c reduction up to 0.9%). In combination with oral antidia-
betic drugs, lixisenatide resulted in a sustained body weight reduc-
tion from baseline in controlled studies (24 weeks) in a range from1.8–3 kg. Comparison of lixisenatide with exenatide BID as add-on
to metformin demonstrated noninferior improvements in HbA1c,
but with less hypoglycemia, slightly less weight loss and a more
favorable gastro-intestinal tolerability proﬁle after 24 weeks.33 Lix-
isenatide signiﬁcantly delays gastric emptying, a process which is
accompanied by strong post-prandial glucose lowering.34 These
attributes are very attractive with regard to a combination therapy
with basal insulins, for example, insulin glargine, where Lixisena-
tide demonstrated signiﬁcantly reduced HbA1C (0.7–0.8%) and
body weight (1.8 kg).34 In February 2013, the EMA granted market-
ing authorization in Europe for lixisenatide for the treatment of
adults with T2DM.35
Sustained release of DPPIV stabilized peptides. DPPIV-resistant
peptidic GLP-1 RAs are still subjected to renal clearance as illus-
trated by the rather moderate half-lives of exenatide and lixisena-
tide. Therefore, several approaches have been explored to further
prolong the duration of action by either creating a depot (e.g. in
the subcutaneous space), from which the peptide is slowly re-
leased, or by conjugating peptidic GLP-1 agonists to carrier mole-
cules in order to reduce renal clearance.
Taspoglutide. Taspoglutide developed by Roche (in collaboration
with Ipsen) is a close analog of natural GLP-1(7–36) in which the
unnatural amino acid aminoisobutyric acid (Aib) has been intro-
duced in position 8 and 35 in order to avoid degradation by DPPIV,
but also by other serine proteases such as plasma kallikrein and
plasmin.36 NMR-studies with taspoglutide showed a similar sec-
ondary structure compared to native GLP-1, but clearly an in-
creased a-helicity in the C-terminal part of the peptide.
Taspoglutide was developed as a sustained release formulation
containing zinc chloride suitable for once-weekly administration.
When injected into the subcutaneous tissue, taspoglutide precipi-
tates and forms a depot. Taspoglutide was studied in several phase
3 studies with a 10 and 20 mg once-weekly dosing regimen, and
showed consistent HbA1c and weight reductions.37–41 Signiﬁcant
weight reductions were only observed with the 20 mg dose.42
Once-weekly taspoglutide was superior to twice-daily exenatide
with respect to glycemic control, while resulting in a similar
weight loss after treatment for 24 and 52 weeks. The overall safety
proﬁle comprising gastro-intestinal tolerability, systemic allergic
reactions and injection-site reactions was clearly worse, especially
the gastro-intestinal side effects, which resulted in a roughly dou-
bled discontinuation rate in patients treated with taspoglutide
compared to exenatide (34 vs 16%). Based on this phase 3 data
Roche decided to stop the development of taspoglutide.43
Exenatide LAR–Bydureon. Further strategies to create a subcuta-
neous depot from which the peptidic GLP-1 RA of choice can be
slowly released utilize polymeric matrices. Exenatide LAR (devel-
oped by Amylin/Lilly/Alkermes–now BMS) is a once-weekly for-
mulation of exenatide, in which exenatide is noncovalently
entrapped into a biodegradable polymeric matrix consisting of
poly(D,L-lactide-co-glycolide) (PLG) forming microspheres.44 Slow
release from the polymeric matrix takes place through diffusion
and microsphere breakdown. Exenatide LAR has a half-life in hu-
mans of 5–6 days. After a 2 mg s.c. injection, steady state plasma
levels of exendin-4 are typically obtained after 6–10 weeks.13 At
that dose HbA1c reductions of 1.3–1.9% were observed. A direct
comparison with exenatide BID revealed a better reduction in
HbA1c (1.9 vs 1.5%) with a similar reduction in body weight (3.6
vs 3.7 kg).45 Different from this efﬁcacy data, a head-to-head com-
parison with liraglutide showed an improved glycemic control fol-
lowing 26 weeks of treatment associated with increased weight
reduction in favor of liraglutide (HbA1c reduction 1.5% vs 1.3%,
body weight reduction 3.6 kg vs 2.7 kg).46 One drawback of exena-
tide LAR is the relatively large needle size (23 gauge), which is used
for administration due to the viscosity of the polymeric suspen-
sion, as well as the quite laborious preparation prior to injection.
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well established strategy to prolong the action of peptides by facil-
itating binding to serum albumin thereby reducing their renal
clearance. Landmark achievements in this area have been the
development of long acting insulin analogs.47,48
Liraglutide. Liraglutide (Victoza) developed by Novo Nordisk is
a close structural homolog to GLP-1(7–37) with 97% sequence
identity to the native hormone. Lys in position 34 is substituted
by Arg and a palmitic acid is conjugated to Lys in position 26 via
a glutamate spacer (see Fig. 2a).20 This combination of spacer
and fatty acid length turned out to be optimal in terms of
in vitro activity and in vivo prolonged duration of action in
pigs.49,50 The mechanisms for prolongation of action are manifold.
Following subcutaneous injection, the peptide is slowly released
from the injection site due to self-association.51 Once it enters
the bloodstream, liraglutide is extensively bound to serum albu-
min (99%), which leads to an increased enzymatic stability to-
wards DPPIV and NEP while reducing renal clearance. The plasma
half-life in humans is 11–13 h.20 Liraglutide was approved in 2009
for the treatment of T2DM. The therapeutic standard dose is 1.2 mg
once-daily with possible increase to 1.8 mg to further improve gly-
cemic control. The HbA1c reductions observed with these dosing
regimens in phase 3 trials were 1.1–1.8% accompanied by a weight
loss of around 2–3 kg (26 week treatment).52 In a direct compari-
son liraglutide once-daily showed signiﬁcant improvements in gly-
cemic control compared with exenatide twice-daily (HbA1c
reduction of 1.12% vs 0.79%).53 Using higher doses (3 mg) liraglu-
tide is also under development (phase 3) for the treatment of obes-
ity54 as well as of obese patients with T2DM.55 In a phase 3a study
liraglutide 3 mg treatment resulted in 6% weight reduction in
overweight to obese people compared to placebo.56 Among the
class of GLP-1 RAs, liraglutide currently seems to be the most effec-
tive agent for the treatment of obesity.
Semaglutide. Semaglutide is a next generation GLP-1 analog
from Novo Nordisk, currently in phase 3 clinical development forFigure 2. Approaches for half-life extension of GLP-1 agonists. (a) Liraglutide and semag
their renal clearance. (b) In albiglutide, two copies of modiﬁed GLP-1 are fused as tandem
linked to the Fc region of immunoglobulin G (IgG) as applied in dulaglutide.T2DM as a once-weekly injection. Semaglutide’s structure is based
on liraglutide, with two further modiﬁcations: Gly in position 8 is
replaced by Aib, a beneﬁcial modiﬁcation already applied in taspo-
glutide. Furthermore, the fatty acid side chain has been modiﬁed
towards a N6-[N-(17-carboxy-1-oxoheptadecyl-L-c-glutamyl[2-
(2-aminoethoxy)ethoxy]acetyl[2-(2-aminoethoxy)ethoxy]acetyl]
residue (see Fig. 2a). The human half-life is 160 h. In a 12 week
phase 2 trial in T2DM patients, semaglutide was tested at 5 doses
(0.1–1.6 mg) once-weekly. Semaglutide P0.2 mg dose depen-
dently reduced HbA1c from baseline up to 1.7% (vs 0.5% reduction
for placebo) and for doses P0.8 mg also body weight by up to
4.8 kg (vs 1.2 kg reduction for placebo).57
Conjugation to albumin. Another half-life prolonging principle is
the (genetic) fusion to recombinant albumin. Human serum albu-
min (HSA) has a molecular weight of 67 kDa.58 The half-life of
albumin in humans is 19 days. PH-dependent recycling mediated
by the neonatal FC receptor (FcRN) has been shown to contribute
to that long half-life.59 When albumin is fused to therapeutic pep-
tides such as GLP-1 RAs, both FcRN mediated recycling as well as
reduced clearance due to the increased molecular weight are
responsible for half-life prolongation.
Albiglutide. In albiglutide, developed by GlaxoSmithKline (GSK),
two copies of GLP-1 are fused as tandem repeat to the N-terminus
of albumin. DPPIV-resistance is achieved by a single substitution,
Ala for Gly, at the DPPIV cleavage site (see Fig. 2b). The tandem re-
peat unit was developed to overcome reduced potency as was seen
when only one GLP-1 moiety was directly fused to albumin, mean-
ing that one GLP-1 moiety of the tandem repeat serves as a spacer
to allow potent binding to the GLP-1 receptor.60 Albiglutide has a
half-life of 6–8 days in humans and is currently in phase 3 for
the treatment of T2DM as once-weekly injection. In a 32-week
head-to-head study comparing albiglutide (50 mg) to once-daily
liraglutide (1.8 mg) (HARMONY 7), albiglutide demonstrated a sta-
tistically signiﬁcant reduction in HbA1c (0.78%) from baseline.61
The rather moderate body weight loss of 0.6 kg seen forlutide carry fatty acids, which facilitate binding to serum albumin thereby reducing
repeat to the N-terminus of albumin. (c) Similar to albumin fusion, peptides can be
M. Lorenz et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4011–4018 4015albiglutide is thought to be linked to limited actions in the CNS due
to its large molecular size.13 A regulatory application for albiglu-
tide was submitted in the US in January 2013.62
CJC-1134-PC. Likewise, in ConjuChem’s CJC-1134-PC, exendin-4
is coupled via its C-terminus to albumin by a chemical linker bear-
ing a terminal maleimide which is used for the chemical conjuga-
tion to a single cystein residue on albumin (see Fig. 2b).63 CJC-
1134-PC has a half-life of 8 days in humans and is currently in
phase 2 trials for the treatment of T2DM as once-weekly injection.
CJC-1134-PC seems to be more potent compared to albiglutide. In
phase 2 trials the once-weekly application of 2 mg led to a HbA1c
reduction of 1.4%. As observed for albiglutide, the effects on weight
were only moderate.64
FC fusion. Similar to albumin fusion, peptides can be linked to
the constant region of immunoglobulin G (IgG), the Fc region
(see Fig. 2c).65 The Fc region of IgG has a half-life of 22 days.66
Likewise, when fusing peptides to the FC region of IgG the protrac-
tion principle is based on reduced renal clearance and FcRN med-
iated receptor recycling.
Dulaglutide. Dulaglutide (Eli Lilly) is a recombinant fusion pro-
tein, which consists of two GLP-1 peptides covalently linked by a
small peptide [tetraglycyl-L-seryltetraglycyl-L-seryltetraglycyl-L-
seryl-L-alanyl] to a human IgG4-Fc heavy chain variant. Compared
to natural GLP-1, the GLP-1 moieties contain amino acid substitu-
tions (Ala8?Gly, Gly26?Glu, Arg36?Gly) to ensure protection
from DPPIV cleavage as well as maintenance of the potency of
the construct. Dulaglutide has a half-life of 4 days and is in ad-
vanced clinical trials as once-weekly injection for the treatment
of T2DM.67 In phase 2 clinical trials dulaglutide showed signiﬁcant
dose-dependent reduction in HbA1c (1.5% for the 1.5 mg dose after
12 weeks) and dose-dependent reductions in body weight. How-
ever, the decrease in body weight was not statistically signiﬁcant
when compared to the placebo group.68 Currently, a large phase
3 program (AWARD studies Nos. 1–7) is ongoing, in which dulaglu-
tide has shown a superior glycemic control compared to exenatide
BID after 6 month of treatment.69 Detailed reports regarding the
efﬁcacy in weight loss in longer studies are not yet available.
Langlenatide (HM11260C). In langlenatide, developed by Hanmi
Pharmaceuticals, an exendin-4 analog is fused via a short polyethyl-
eneglycol (PEG) linker to a nonglycosylated Fc region (‘LAPS-carrier’).
In contrast todulaglutideonlyonepeptidecopy is fused to theFc-car-
rier. Such monomeric peptide-Fc-fusion constructs hold promise to
show even higher in vivo efﬁcacy and longer duration of action. In
fact, the half-life of langlenatide has been reported to be 150 h.70
Langlenatide is currently being investigated in phase 2 trials for the
treatmentof T2DMasonce-weekly injection (1–4 mgdoses), but also
for its suitability as once-monthly application (8–16 mg).71
Peptides coupled to biological polymers–Xtenylation. Xtenylation,
which is the genetic fusion of an unstructured recombinant poly-
peptide to a peptide or protein, is a further generic approach to ex-
tend plasma half-life of peptides, again by reducing renal
clearance. The Xten protein is a nonrepetitive amino acid polymer,
which comprises 864 amino acids selected from Ser, Ala, Pro, Thr,
Glu and Gly, with a huge hydrodynamic volume and good serum
stability.72 In contrast to polyethyleneglycol (PEG), Xten is highly
biodegradable which might be beneﬁcial with respect to safety.
VRS-859: In VRS-859, Xten is genetically fused to exenatide. The
product shows a half-life in cynomolgous monkeys of 3 days.
VRS-859 is currently being developed by Diartis Pharmaceuticals
as once-monthly treatment for patients with T2DM. In October
2012, phase 1 results in T2DM patients were disclosed showing
statistically signiﬁcant reductions in HbA1c levels at 30 days after
only one 200 mg dose of VRS-859, supporting the once-monthly
dosing regimen.73
Novel approaches and combination of multiple hormone actions.
Approximately 70–80% of severely obese patients with T2DMwho undergo bariatric surgery show signiﬁcant and fast improve-
ment of glycemic control even up to a complete remission of dia-
betes, often resulting in discontinuation of insulin or oral anti-
diabetic therapy.74 The mechanism seems partly independent of
weight reduction and related to alterations in the release of gas-
tro-intestinal hormones, for example increased plasma levels of
GLP-1, oxyntomodulin and peptide YY (PYY). In addition to the ef-
fects of GLP-1, these peptides are known to be involved in the reg-
ulation of glucose homeostasis, food intake and energy
expenditure.75 Based on the impressive improvements of T2DM
after bariatric surgery, trying to mimic some alterations in plasma
levels of these peptide hormones is a highly attractive research ef-
fort to identify novel therapeutic options for obese patients with
T2DM. Combining dual or triple agonistic effects in a single peptide
(feasible if peptides are sufﬁciently similar) or combining 2 distinct
peptides in a formulation approach are possible options. Slow re-
lease formulations/delivery approaches as mentioned above could
prolong the duration of action from once-daily up to a once-weekly
administration regimens.
Below we discuss promising combinations of peptides, which
have the potential for improved glycemic control associated with
more effective weight reduction compared to pure GLP-1 RAs.
GLP-1/glucagon co-agonists. Oxyntomodulin is a 37 amino acid
peptide (comprising the entire 29 amino acid sequence from gluca-
gon plus a C-terminal extension of 8 residues) secreted by intesti-
nal L-cells (together with GLP-1 and PYY) following meal ingestion.
The dual agonistic activity of oxyntomodulin is weaker for the GLP-
1 and glucagon receptors when compared to the cognate native li-
gands GLP-1 and glucagon.76 Originally glucagon was discovered as
a hormone with effects counter to those of insulin, raising blood
glucose levels by stimulating gluconeogenesis and glycogenolysis
to circumvent a hypoglycemic state. However, more recent data
in rodents and humans reveal that glucagon could have beneﬁcial
effects on energy balance, body fat mass and nutrient intake. Those
effects seem to be mediated at least in part by FGF21-dependent
pathways.77,78
In overweight and obese people native oxyntomodulin was
shown to signiﬁcantly reduce body weight by 1.7 kg vs. placebo
following three-times subcutaneous administration (to compen-
sate for the short half-life of the native peptide) for 4 weeks.79
Furthermore, oxyntomodulin was mechanistically proven to re-
duce food intake after an ad libitum test meal and increase energy
expenditure in humans.80 Thus, combining the actions of GLP-1
and glucagon in one molecule like in oxyntomodulin might lead
to a therapeutic principle with anti-diabetic action related to the
GLP-1 component and a pronounced weight lowering effect related
to glucagon receptor stimulation. Pioneering work in the ﬁeld was
carried out by Bloom and co-workers,81 DiMarchi and co-workers82
and Merck Research Laboratories.83 Chemical strategies in order to
identify such GLP-1/glucagon co-agonists started either from the
sequence of oxyntomodulin or glucagon by carefully incorporating
amino acids known to be relevant for GLP-1 agonism but also ele-
ments to prolong half-life. A Tschöp, model peptide is shown in
Figure 3, which is a hybrid peptide derived from native GLP-1
and glucagon. Further chemical modiﬁcations to increase the sta-
bility and in vivo half-life include a lactam bond between the
side-chains of Glu in position 16 and Lys in position 20 (‘stapling’)
and the addition of a linear 40 kDa PEG chain to Cys in position 24.
For the design of novel stabilized peptides the selection of the
activity-ratio for the GLP-1 and the glucagon receptor is important
for adjusting the right balance between anti-diabetic and anti-
obesity effects. High potency at the glucagon receptor can be
anticipated to strongly increase weight loss but potentially at the
expense of elevated glucose levels. Data in mice suggest that a
balanced ratio of GLP-1/glucagon-receptor activation (1:1) is
optimal to ensure glucose control associated with improved
Figure 3. Amino acid sequence of native GLP-1, native glucagon and a representative chimeric peptide82 which shows balanced activity on both, the GLP-1 and glucagon
receptor. Amino acids, which are identical to GLP-1 are colored green, residues unique to glucagon are shown in yellow and further modiﬁcations are shown in orange. These
modiﬁcations include a lactam bond between Glu in position 16 and Lys in position 20 (‘stapling’) and the addition of a linear 40 kDa PEG chain to Cys in position 24.
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ation has to be proven in clinical settings. A number of compounds
have progressed into phase 1, among those ZP2929, which is a GLP-
1/Glucagon co-agonist carrying a fatty acid for once-daily dosing
from Zealand Pharma (now in collaboration with Boehringer Ingel-
heim),85 and TT401 from Transition Therapeutics, which is a PEGy-
lated analog for once-weekly dosing.86
GLP-1/GIP co-agonists. The incretin effect refers to enhanced
insulin secretion following an oral glucose load relative to an iso-
glycemic challenge after intravenous administration and is caused
by the two incretin hormones, GLP-1 and glucose-dependent insu-
linotropic polypeptide (GIP). The gut-derived peptide hormone GIP
is released by gastro-intestinal K-cells following meal ingestion.
GIP shares 37% amino acid sequence identity with GLP-1 and
shows a helical character with many conserved or similar amino
acids facing the binding groove of the extracellular domain of the
GIP receptor that is structurally similar to the GLP-1 receptor.10,87
According to the similarity of the interaction sites, designing single
peptides with activity for both incretin hormone receptors is feasi-
ble. Since both hormones account equally for 50–70% of the over-
all meal stimulated insulin secretion in humans,88 a more
pronounced anti-diabetic effect of such dual agonistic peptides
compared to sole GLP-1 RAs could be expected. Preclinical data
for potent GLP-1/GIP dual agonistic peptides show signiﬁcantly
better reduction of blood glucose levels and body weight in diet-in-
duced obesity (DIO) mice compared to liraglutide following once-
daily treatment for one week.89 Furthermore, such a GLP-1/GIP
co-agonist was also shown to be superior to liraglutide with re-
spect to glycemic control in a clamp study in nonhuman
primates.90
Of note, in patients with T2DM the incretin effect is generally
impaired and this is considered to be mainly related to a decreased
GIP-activity of the b-cell.91 On that basis, a prerequisite for consid-
ering dual GLP-1/GIP receptor agonists as therapeutic option for
T2DM is the reversibility of the reduced response of the b-cell to
GIP. Indeed, studies in patients with T2DM indicate an ameliora-
tion of the insulinotropic effect of GIP when the diabetic status is
improved, for example, following moderate life-style induced
weight loss of 5 kg, 4 weeks of intensive insulin treatment or
therapy with sulfonylureas.92–94 Furthermore, there is preclinical
evidence in Zucker diabetic rats that the reduced insulinotropic ef-
fect of GIP is related to down-regulation of the respective receptor.
Two weeks treatment with phlorizin (an unspeciﬁc SGLT 1/2-
inhibitor) could reestablish receptor expression, which is
associated with GIP-induced insulin secretion not observed in the
placebo group that was not treated with phlorizin.95 Marcadia,
which was acquired by Roche in late 2010, was pioneering this ap-
proach. A ﬁrst PEGylated compound, Mar701 (RO-6807952), was
evaluated in phase 1 clinical settings, among those a 8 weeks study
in patients with T2DM on top of metformin. However, that
compound was discontinued in September 2012 and replaced by
a follow-up compound MAR709 (RG7697/RO6811135), now
undergoing phase 1 evaluation.96,97GLP-1/PYY Combination. Peptide YY (PYY), named by the Tyr (Y)
residues at each end of its 36 amino acid chain, is a further gut-de-
rived hormone, which is also postprandially secreted from intesti-
nal L-cells into the blood circulation. Following rapid cleavage by
DPPIV, PYY(3–36) is generated in plasma, which is a selective ago-
nist for the neuropeptide Y2 receptor. PYY(3–36) was proven to in-
hibit food intake in humans and showed improved insulin
sensitivity in rodents. Furthermore, PYY deﬁciency is discussed to
contribute to the pathogenesis of obesity.98,99 Along these lines, a
combination approach of GLP-1 and PYY seems an attractive option
for the treatment of diabesity. Because GLP-1 and PYY lack sufﬁ-
cient similarity, both peptides need to be co-administered. This
concept is supported by preclinical data from GSK studying the
combination of exendin-4 and PYY constructs fused to an albu-
min-binding antibody fragment. Following subcutaneous adminis-
tration every second day over a period of 15 days to diabetic mice
(db/db), HbA1c as well as body weight were dramatically reduced
suggesting a synergistic effect compared to treatment with each
single agent.100
Conclusion and outlook. Life-style changes comprising diet and
exercise are the ﬁrst recommendations for patients newly diag-
nosed with T2DM in order to reduce body weight and thereby to
reduce hyperglycemia and decrease the associated cardiovascular
risk.5 This recommendation underlines the importance of weight
loss in T2DM especially since prevalence and incidence of T2DM
in conjunction with rising obesity rates are increasing worldwide.
Thus, there is a high medical need for novel anti-diabetic agents
associated with effective weight lowering properties. The mar-
keted GLP-1 RAs have proven successfully such twofold therapeu-
tic beneﬁt by reducing hyperglycemia and body weight to meet
this need. Upcoming phase 3 data from the next generation of
long-term GLP-1 RAs will show if the efﬁcacy within the class
can be further improved without impacting safety. A third wave
of therapeutic peptides with combined anti-diabetic and anti-
obesity effects are peptidic co-agonists comprising the activity of
GLP-1 plus additional gastro-intestinal hormones. Single peptides
with dual or even trigonal agonistic activity as well as combina-
tions of two separate peptides with different, but additive effects
might have the potential for increased efﬁcacy, especially with re-
spect to body weight reduction, over the class of pure GLP-1 RAs.
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